Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Department of Radiology, Division of Nuclear Radiology, Mayo Clinic, Rochester, Minnesota.
Am J Hematol. 2019 Jul;94(7):786-793. doi: 10.1002/ajh.25493. Epub 2019 May 16.
Predicting early clinical failure in patients with untreated follicular lymphoma (FL) is important but difficult. This study aimed to determine the incidence and patterns of extranodal (EN) and spleen disease using PET/CT, and assess their utility in predicting early clinical failure. PET/CT images from 613 cases of untreated FL (2003-2016) were reviewed. The location and number of EN sites, patterns of bone involvement, and splenic involvement were recorded. Outcomes were assessed using event-free survival (EFS), overall survival (OS), and early clinical failure at 24 months (EFS24). So, 49% (301/613) of patients had PET/CT-detected EN involvement, and 28% (171/613) had spleen involvement. The presence of ≥2 EN sites, spleen, bone or soft tissue involvement all predicted failure to achieve EFS24. Presence of ≥2 EN sites and bone involvement pattern were also predictive of OS in a univariate analysis. In a multivariate analysis with FLIPI-2 factors, spleen involvement, pattern of bone involvement, and soft tissue involvement independently predicted a lower EFS (HR 1.49 (1.11-2.00), P = .007; HR 1.71 (1.10-2.65), P = .017; and HR 1.67 (1.06-2.62), P = .026, respectively). When the multivariate analysis was performed using PRIMA-PI factors (marrow and B2M), the number of EN sites was an independent prognostic factor for inferior OS (HR 2.28; P = .05). Baseline PET/CT identifies EN involvement in nearly half of patients with untreated FL. The presence of ≥2 EN sites, bone, soft tissue, or splenic involvement predicts early clinical failure. These results, when combined with other factors, may better identify high-risk patients and guide therapy.
预测未经治疗的滤泡性淋巴瘤(FL)患者的早期临床失败很重要,但也很困难。本研究旨在通过 PET/CT 确定结外(EN)和脾脏疾病的发生率和模式,并评估其在预测早期临床失败中的作用。回顾了 613 例未经治疗的 FL(2003-2016 年)的 PET/CT 图像。记录了 EN 部位的位置和数量、骨受累模式和脾脏受累情况。使用无事件生存(EFS)、总生存(OS)和 24 个月时的早期临床失败(EFS24)评估结局。因此,49%(301/613)的患者有 PET/CT 检测到的 EN 受累,28%(171/613)的患者有脾脏受累。存在≥2 个 EN 部位、脾脏、骨或软组织受累均预测无法达到 EFS24。在单变量分析中,存在≥2 个 EN 部位和骨受累模式也可预测 OS。在多变量分析中,加入 FLIPI-2 因素后,脾脏受累、骨受累模式和软组织受累可独立预测 EFS 较低(HR 1.49(1.11-2.00),P =.007;HR 1.71(1.10-2.65),P =.017;和 HR 1.67(1.06-2.62),P =.026)。当使用 PRIMA-PI 因素(骨髓和 B2M)进行多变量分析时,EN 部位数量是 OS 较差的独立预后因素(HR 2.28;P =.05)。基线 PET/CT 可识别近一半未经治疗的 FL 患者的 EN 受累。存在≥2 个 EN 部位、骨、软组织或脾脏受累可预测早期临床失败。这些结果与其他因素结合使用,可能更好地识别高危患者并指导治疗。